183 related articles for article (PubMed ID: 23664487)
1. CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.
Zhang J; Chang B; Liu J
Hum Pathol; 2013 Sep; 44(9):1882-9. PubMed ID: 23664487
[TBL] [Abstract][Full Text] [Related]
2. Correlation of CD44v6 expression with ovarian cancer progression and recurrence.
Shi J; Zhou Z; Di W; Li N
BMC Cancer; 2013 Apr; 13():182. PubMed ID: 23565736
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
4. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.
Kayastha S; Freedman AN; Piver MS; Mukkamalla J; Romero-Guittierez M; Werness BA
Clin Cancer Res; 1999 May; 5(5):1073-6. PubMed ID: 10353740
[TBL] [Abstract][Full Text] [Related]
5. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas.
Ross JS; Sheehan CE; Williams SS; Malfetano JH; Szyfelbein WM; Kallakury BV
Am J Clin Pathol; 2001 Jul; 116(1):122-8. PubMed ID: 11447742
[TBL] [Abstract][Full Text] [Related]
6. CD44 Immunoexpression is Unfavorable Predictor in Ovarian Serous Cancer.
Karan Križanac D; Krasić Arapović A; Skočibušić S; Pintarić I; Trgo G; Tomić S
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):398-402. PubMed ID: 27490763
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
[TBL] [Abstract][Full Text] [Related]
8. Sex-determining region Y-box 2 expression predicts poor prognosis in human ovarian carcinoma.
Zhang J; Chang DY; Mercado-Uribe I; Liu J
Hum Pathol; 2012 Sep; 43(9):1405-12. PubMed ID: 22401770
[TBL] [Abstract][Full Text] [Related]
9. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
10. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.
Liu M; Mor G; Cheng H; Xiang X; Hui P; Rutherford T; Yin G; Rimm DL; Holmberg J; Alvero A; Silasi DA
Reprod Sci; 2013 May; 20(5):605-15. PubMed ID: 23171677
[TBL] [Abstract][Full Text] [Related]
11. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
[TBL] [Abstract][Full Text] [Related]
12. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas.
Afify AM; Ferguson AW; Davila RM; Werness BA
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):309-14. PubMed ID: 11759056
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
Cho EY; Choi Y; Chae SW; Sohn JH; Ahn GH
Pathol Int; 2006 Feb; 56(2):62-70. PubMed ID: 16445817
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis.
Zhao L; Gu C; Huang K; Zhang Z; Ye M; Fan W; Han W; Meng Y
Arch Gynecol Obstet; 2016 Nov; 294(5):1019-1029. PubMed ID: 27300001
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications.
Berner HS; Davidson B; Berner A; Risberg B; Kristensen GB; Trope CG; Van de Putte G; Nesland JM
Clin Exp Metastasis; 2000; 18(2):197-202. PubMed ID: 11235996
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CD44s expression in resected non-small cell lung cancer.
Ko YH; Won HS; Jeon EK; Hong SH; Roh SY; Hong YS; Byun JH; Jung CK; Kang JH
BMC Cancer; 2011 Aug; 11():340. PubMed ID: 21819617
[TBL] [Abstract][Full Text] [Related]
20. CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer.
Motohara T; Fujimoto K; Tayama S; Narantuya D; Sakaguchi I; Tashiro H; Katabuchi H
Obstet Gynecol; 2016 Jun; 127(6):1003-1011. PubMed ID: 27159753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
